ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q1 2025 vs. Q4 2024
How the institutions holding ArriVent BioPharma, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 80 | 1 | 83 | +4 |
| Shares | 28.5M | 44.3K | 29.1M | +653.5K (+2.3%) |
| Value | $757.5M | $1.18M | $539.3M | −$217.0M (−28.7%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held ArriVent BioPharma, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nuveen, LLC | 44,282 | $818.8K | 0.00% |
| Two Sigma Investments, LP | 41,381 | $765.1K | 0.00% |
| Marshall Wace, LLP | 35,851 | $662.9K | 0.00% |
| ExodusPoint Capital Management, LP | 22,268 | $412.0K | 0.01% |
| Squarepoint Ops LLC | 18,426 | $340.7K | 0.00% |
| Two Sigma Advisers, LP | 18,000 | $332.8K | 0.00% |
| Tudor Investment Corp Et Al | 15,293 | $282.8K | 0.00% |
| Dynamic Technology Lab Private Ltd | 14,379 | $266.0K | 0.04% |
| Sectoral Asset Management Inc | 10,090 | $186.6K | 0.15% |
| Virtus Investment Advisers, Inc. | 6,348 | $117.4K | 0.03% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 457 | $8.45K | 0.00% |
| Lindbrook Capital, LLC | 118 | $2.18K | 0.00% |
| Allworth Financial LP | 29 | $614 | 0.00% |
| Parkside Financial Bank & Trust | 20 | $370 | 0.00% |
| Covestor Ltd | 4 | $0 | 0.00% |
Sold out (11)
Institutions that held ArriVent BioPharma, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Cormorant Asset Management, LP | 585,462 | $15.6M |
| ProShare Advisors LLC | 9,532 | $253.9K |
| AQR Capital Management LLC | 8,868 | $236.2K |
| Voya Investment Management LLC | 8,373 | $223.1K |
| UBS Asset Management Americas Inc | 8,165 | $217.5K |
| Virtus ETF Advisers LLC | 2,747 | $73.2K |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 996 | $26.5K |
| SRS Capital Advisors, Inc. | 119 | $3.17K |
| Quadrant Capital Group LLC | 21 | $560 |
| Advisor Group Holdings, Inc. | 17 | $453 |
| Parallel Advisors, LLC | 3 | $80 |
Not filed for Q1 2025 yet (1)
Institutions that held ArriVent BioPharma, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 44,282 | $1.18M |